<DOC>
	<DOCNO>NCT00969761</DOCNO>
	<brief_summary>The primary objective trial identify maximum tolerate dose ( MTD ) BI 6727 therapy term drug-related adverse event combine platinum therapy ( cisplatin carboplatin ) . Secondary objective collection overall safety antitumour efficacy data determination pharmacokinetic profile BI 6727 combination treatment cisplatin carboplatin .</brief_summary>
	<brief_title>BI 6727 ( Volasertib ) Combination With Cisplatin Carboplatin Patients With Advanced Metastatic Solid Tumour</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients confirm diagnosis advance , non resectable / metastatic solid tumour , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment 2 . Indication treatment platinum therapy judge investigator 3 . Age 18 year old 4 . Written inform consent consistent ICHGCP local legislation 5 . ECOG performance score low equal 2 6 . Recovery CTCAE Grade 2 4 therapyrelated toxicity previous systemic anticancer therapy radiotherapy ( except alopecia grade 2 ) Exclusion criterion : 1 . Serious illness concomitant nononcological disease consider investigator incompatible protocol 2 . Pregnancy breastfeed 3 . Active infectious disease know chronic Hepatitis B/Hepatitis C infection HIV I/II 4 . Clinical evidence symptomatic progressive brain leptomeningeal disease past 6 month 5 . Second malignancy currently require another anticancer therapy 6 . ANC le 1500 / mm3 7 . Platelet count less 100 000 / mm3 8 . Bilirubin great 1.5 mg / dl ( &gt; 26 micromol / L , SI unit equivalent ) ( except Gilbert 's syndrome ) 9 . Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis great five time upper limit normal ) 10 . Serum creatinine great 1.5 mg / dl ( &gt; 132 micromol / L , SI unit equivalent ) creatinine clearance &lt; 70ml/min ( calculate accord CockcroftGault formula GFR estimate ) 11 . Known history relevant QTprolongation , e.g . long QTsyndrome 12 . Preexisting clinically relevant hearing loss 13 . Women men sexually active unwilling use medically acceptable method contraception 14 . Treatment investigational drug participation another clinical interventional trial within past four week start therapy concomitantly trial 15 . Systemic anticancer therapy radiotherapy within past four week start therapy concomitantly trial . This restriction apply steroids bisphosphonates . 16 . Patients unable comply protocol 17 . Active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>